VVT Medical has announced a milestone in its production and cost reduction initiatives.
A press release reports that, in July 2024, the company inaugurated a new catheter production line in Mauritius.
VVT Medical details that this production site offers ultramodern manufacturing technologies and controlled assembly areas. The facility includes dedicated cleanrooms certified to ISO 5 and ISO 7 standards, equipped with HEPA filters and strict environmental monitoring. It also houses machine and equipment design areas, and a segregated inspection area for raw materials and lot release testing. With its expansion strategy, VVT Medical notes that the additional space will be available for custom-built cleanrooms.
The coaxial, monorail, double-lumen ScleroSafe catheter accounts for a significant portion of the total ScleroSafe kit cost, a press release shares. While the catheter is currently manufactured in the USA, to facilitate growth, VVT Medical seeks to identify additional manufacturing capabilities, potentially decreasing manufacturing costs and improving our gross margins.
In 12 months, the company notes that its team identified, developed, deployed, executed, and completed the accreditation of a mass production scale production line for the ScleroSafe catheter.
VVT Medical details key accomplishments from this initiative, which include:
- A major cost reduction per catheter.
- An extensive increase in production capacity with the potential for further scale-up without additional capital investment.
“At VVT Medical, we’re dedicated to transforming lives. We’re working around the clock to scale up and fulfill our mission of reaching as many patients as possible with our non-thermal, anaesthesia-free, and painless treatments to eliminate varicose veins,” said Erez Tetro, chief executive officer of VVT Medical. “I am happy to announce this great milestone that will bring us much closer to achieving that goal.”
